BSLKW
Bolt Projects Holdings, Inc.
Financial - Conglomerates
Market Cap$4K
5Y Perf.-97.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BSLKW vs KTTA
Revenue, margins, valuation, and 5-year total return — side by side.
KTTA
Pasithea Therapeutics Corp.
Biotechnology
Market Cap$19M
5Y Perf.-86.8%
BSLKW vs KTTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BSLKW | KTTA |
|---|---|---|
| Industry | Financial - Conglomerates | Biotechnology |
| Market Cap | $4K | $19M |
| Revenue (TTM) | $1M | $0.00 |
| Net Income (TTM) | $-24M | $-13M |
| Gross Margin | -6.8% | — |
| Operating Margin | -30.3% | — |
| Total Debt | $13M | $0.00 |
| Cash & Equiv. | $4M | $7M |
BSLKW vs KTTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BSLKW
KTTA
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Bolt Projects Holdi… (BSLKW) | 100 | 2.7 | -97.3% |
| Pasithea Therapeuti… (KTTA) | 100 | 13.2 | -86.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BSLKW vs KTTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KTTA leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
BSLKW
Bolt Projects Holdings, Inc.
The Banking Pick
BSLKW is the clearest fit if your priority is long-term compounding.
- -97.4% 10Y total return vs KTTA's -98.8%
Best for: long-term compounding
KTTA
Pasithea Therapeutics Corp.
The Growth Play
KTTA carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 2.5%
- Lower volatility, beta 0.92, current ratio 6.58x
- Beta 0.92, current ratio 6.58x
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KTTA | 15.2% revenue growth vs BSLKW's -60.1% |
| Quality / Margins | KTTA | 2.6% margin vs BSLKW's -47.6% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KTTA | -25.7% vs BSLKW's -76.0% |
| Efficiency (ROA) | KTTA | -88.0% ROA vs BSLKW's -218.1% |
BSLKW vs KTTA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKTTALAGGINGBSLKW
BSLKWBolt Projects Holding…
0leads
KTTAPasithea Therapeutics…
4leads
6 Total Categories
CATEGORYLEADERvs BSLKWMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KTTA1/1
Valuation MetricsMultiples, price ratios, and targets
KTTA1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KTTA4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
KTTA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KTTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BSLKW and KTTA operate at a comparable scale, with $1M and $0 in trailing revenue.
| Metric | BSLKWBolt Projects Hol… | KTTAPasithea Therapeu… |
|---|---|---|
| RevenueTrailing 12 months | $1M | $0 |
| EBITDAEarnings before interest/tax | -$20M | -$13M |
| Net IncomeAfter-tax profit | -$24M | -$13M |
| Free Cash FlowCash after capex | -$5M | -$12M |
| Gross MarginGross profit ÷ Revenue | -6.8% | — |
| Operating MarginEBIT ÷ Revenue | -30.3% | — |
| Net MarginNet income ÷ Revenue | -47.6% | — |
| FCF MarginFCF ÷ Revenue | -11.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -142.1% | +85.7% |
KTTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
KTTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | BSLKWBolt Projects Hol… | KTTAPasithea Therapeu… |
|---|---|---|
| Market CapShares × price | $3,789 | $19M |
| Enterprise ValueMkt cap + debt − cash | $10M | $12M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.07x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.00x | — |
| Price / BookPrice ÷ Book value/share | — | 0.06x |
| Price / FCFMarket cap ÷ FCF | — | — |
KTTA leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
KTTA leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BSLKW scores 5/9 vs KTTA's 2/9, reflecting solid financial health.
| Metric | BSLKWBolt Projects Hol… | KTTAPasithea Therapeu… |
|---|---|---|
| ROE (TTM)Return on equity | — | -97.9% |
| ROA (TTM)Return on assets | -2.2% | -88.0% |
| ROICReturn on invested capital | — | -142.4% |
| ROCEReturn on capital employed | -35.0% | -74.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $10M | -$7M |
| Cash & Equiv.Liquid assets | $4M | $7M |
| Total DebtShort + long-term debt | $13M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -14.88x | — |
KTTA leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
KTTA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BSLKW five years ago would be worth $263 today (with dividends reinvested), compared to $118 for KTTA. Over the past 12 months, KTTA leads with a -25.7% total return vs BSLKW's -76.0%. The 3-year compound annual growth rate (CAGR) favors KTTA at -50.9% vs BSLKW's -70.3% — a key indicator of consistent wealth creation.
| Metric | BSLKWBolt Projects Hol… | KTTAPasithea Therapeu… |
|---|---|---|
| YTD ReturnYear-to-date | -70.9% | -29.4% |
| 1-Year ReturnPast 12 months | -76.0% | -25.7% |
| 3-Year ReturnCumulative with dividends | -97.4% | -88.2% |
| 5-Year ReturnCumulative with dividends | -97.4% | -98.8% |
| 10-Year ReturnCumulative with dividends | -97.4% | -98.8% |
| CAGR (3Y)Annualised 3-year return | -70.3% | -50.9% |
KTTA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BSLKW and KTTA each lead in 1 of 2 comparable metrics.
Risk & Volatility
BSLKW is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than KTTA's 0.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KTTA currently trades 40.8% from its 52-week high vs BSLKW's 3.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BSLKWBolt Projects Hol… | KTTAPasithea Therapeu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | 0.92x |
| 52-Week HighHighest price in past year | $0.15 | $2.06 |
| 52-Week LowLowest price in past year | $0.00 | $0.28 |
| % of 52W HighCurrent price vs 52-week peak | +3.2% | +40.8% |
| RSI (14)Momentum oscillator 0–100 | 45.7 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 24K | 457K |
Evenly matched — BSLKW and KTTA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BSLKWBolt Projects Hol… | KTTAPasithea Therapeu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KTTA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallPasithea Therapeutics Corp. (KTTA)Leads 4 of 6 categories
Loading custom metrics...
BSLKW vs KTTA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — BSLKW or KTTA?
Over the past 5 years, Bolt Projects Holdings, Inc.
(BSLKW) delivered a total return of -97. 4%, compared to -98. 8% for Pasithea Therapeutics Corp. (KTTA). Over 10 years, the gap is even starker: BSLKW returned -97. 4% versus KTTA's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BSLKW or KTTA?
By beta (market sensitivity over 5 years), Bolt Projects Holdings, Inc.
(BSLKW) is the lower-risk stock at -0. 11β versus Pasithea Therapeutics Corp. 's 0. 92β — meaning KTTA is approximately -962% more volatile than BSLKW relative to the S&P 500.
03Which is growing faster — BSLKW or KTTA?
On earnings-per-share growth, the picture is similar: Pasithea Therapeutics Corp.
grew EPS 2. 5% year-over-year, compared to -13. 3% for Bolt Projects Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — BSLKW or KTTA?
Pasithea Therapeutics Corp.
(KTTA) is the more profitable company, earning 0. 0% net margin versus -47. 6% for Bolt Projects Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KTTA leads at 0. 0% versus -30. 3% for BSLKW. At the gross margin level — before operating expenses — KTTA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BSLKW or KTTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is BSLKW or KTTA better for a retirement portfolio?
For long-horizon retirement investors, Bolt Projects Holdings, Inc.
(BSLKW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Both have compounded well over 10 years (BSLKW: -97. 4%, KTTA: -98. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BSLKW and KTTA?
These companies operate in different sectors (BSLKW (Financial Services) and KTTA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Closest Rival
Compare KTTA vs CMPS
CMPS is one of the most direct listed alternatives to KTTA.
Closest Rival
Compare BSLKW vs CLNN
CLNN is one of the most direct listed alternatives to BSLKW.
Expand Peer Set
Expand With PRAX + SAVA
PRAX and SAVA are the strongest missing peers across the current compare set.